{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:22:36Z","timestamp":1784254956203,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>AURIGA ist die gr\u00f6\u00dfte prospektive Real-world-Studie zur Behandlung des diabetischen Makula\u00f6dems (DM\u00d6) bzw. des Makula\u00f6dems nach retinalem Venenverschluss mit intravitrealem Aflibercept (IVT-AFL). Hier werden die 24-Monatsdaten der deutschen behandlungsnaiven DM\u00d6-Kohorte pr\u00e4sentiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Behandlungsnaive DM\u00d6-Patienten wurden mit IVT-AFL in der klinischen Routine therapiert. Prim\u00e4rer Endpunkt war die mittlere \u00c4nderung des Visus (ETDRS-Buchstaben) zu Monat\u00a012 gegen\u00fcber dem Ausgangswert. Die Analyse erfolgte deskriptiv.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die Analyse umfasst Daten von 150\u00a0DM\u00d6-Patienten (54,7\u202f% m\u00e4nnlich). Zu Monat\u00a06, 12 und\u00a024 wurden im Mittel (95\u202f%-Konfidenzintervall) Visusgewinne von\u00a04,6 (2,6; 6,5), 4,0 (2,1; 6,5) und\u00a05,0 (3,0; 6,9) Buchstaben im Vergleich zum Ausgangswert (Mittel \u00b1SD: 65,0\u202f\u00b1\u200915,3 Buchstaben) sowie eine Reduktion der Netzhautdicke um\u00a086 (109; 64) \u00b5m, 70 (94; 43) \u00b5m und 75 (103; 47) \u00b5m vom Ausgangswert (Mittel \u00b1SD: 391\u202f\u00b1\u2009132\u202f\u00b5m) erreicht. Zu Monat\u00a024 hatten 54\u202f% der Patienten \u2265\u202f5\u00a0Buchstaben gewonnen und 22\u202f% \u2265\u202f15\u00a0Buchstaben. Die mittlere Injektionszahl betrug 5,0\u202f\u00b1\u20091,6 bis Monat\u00a06, 7,1\u202f\u00b1\u20093,2 bis Monat\u00a012 und 9,0\u202f\u00b1\u20095,3 bis Monat\u00a024. 68\u202f% der DM\u00d6-Patienten erhielten \u2265\u202f5\u00a0Injektionen bis Monat\u00a06, 56\u202f% \u2265\u202f7\u00a0Injektionen im ersten Jahr. Das Sicherheitsprofil entsprach dem fr\u00fcherer AFL-Studien.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>In der deutschen AURIGA-Kohorte behandlungsnaiver DM\u00d6-Patienten unter IVT-AFL-Behandlung im klinischen Alltag zeigten sich ein z\u00fcgiger und klinisch relevanter Visusgewinn sowie eine Reduktion der zentralen Netzhautdicke. Beides wurden ab Monat\u00a06 mit reduzierter Injektionsfrequenz \u00fcber 24\u00a0Monate erhalten. Im Vergleich zu fr\u00fcheren Real-world-Studien deutet sich zwar eine verbesserte Versorgungsqualit\u00e4t von DM\u00d6-Patienten im klinischen Alltag an, dennoch besteht weiteres Optimierungspotenzial.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-024-02110-9","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T13:16:11Z","timestamp":1726665371000},"page":"894-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aflibercept im klinischen Alltag: die AURIGA-Studie","Aflibercept in the clinical routine: the AURIGA study"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5961-0039","authenticated-orcid":false,"given":"Michael","family":"Ulbig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Karl","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Mirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Allmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Machewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Keramas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Khoramnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Studien\u00e4rzte der AURIGA-Studie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"2110_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ophtha.2022.12.008","volume":"130","author":"CW Baker","year":"2023","unstructured":"Baker\u00a0CW, Josic\u00a0K, Maguire\u00a0MG et\u00a0al (2023) DRCR Retina Network. Comparison of Snellen Visal Acuity Measurements in Retinal Clinical Practice to Electronic ETDRS Protocol Visual Acuity Assessment. Ophthalmology 130:533\u2013541","journal-title":"Ophthalmology"},{"key":"2110_CR2","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","volume":"122","author":"DM Brown","year":"2015","unstructured":"Brown\u00a0DM, Schmidt-Erfurth\u00a0U, Do\u00a0DV et\u00a0al (2015) Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122:2044\u20132052","journal-title":"Ophthalmology"},{"key":"2110_CR3","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","volume":"66","author":"DJ Browning","year":"2018","unstructured":"Browning\u00a0DJ, Stewart\u00a0MW, Lee\u00a0C (2018) Diabetic macular edema: Evidence-based management. Indian J Ophthalmol 66:1736\u20131750","journal-title":"Indian J Ophthalmol"},{"key":"2110_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","volume":"105","author":"TA Ciulla","year":"2021","unstructured":"Ciulla\u00a0TA, Pollack\u00a0JS, Williams\u00a0DF (2021) Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a\u00a0real-world analysis of 28 658 patient eyes. Br J Ophthalmol 105:216\u2013221","journal-title":"Br J Ophthalmol"},{"key":"2110_CR5","unstructured":"ClinicalTrials.gov PHOTON. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04429503?term=NCT04429503&draw=2&rank=1"},{"key":"2110_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","volume":"63","author":"A Dariuch","year":"2018","unstructured":"Dariuch\u00a0A, Matete\u00a0AA, Moulin\u00a0AA et\u00a0al (2018) Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res 63:20\u201368","journal-title":"Prog Retin Eye Res"},{"key":"2110_CR7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells\u00a0JA, Glassman\u00a0AR et\u00a0al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N\u00a0Engl J Med 372:1193\u20131203","journal-title":"N Engl J Med"},{"key":"2110_CR8","first-page":"2637","volume":"64","author":"S Donati","year":"2023","unstructured":"Donati\u00a0S, Yang\u00a0CH, Mura\u00a0M et\u00a0al (2023) Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study. Ophthalmol Ther 64:2637","journal-title":"Ophthalmol Ther"},{"key":"2110_CR9","unstructured":"Fachinformation Aflibercept."},{"key":"2110_CR10","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori\u00a0NZ, Feuer\u00a0W, Rosenfeld\u00a0PJ (2010) Novel method for analyzing Snellen visual acuity measurements. Retina 30:1046\u20131050","journal-title":"Retina"},{"key":"2110_CR11","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier\u00a0JS, Korobelnik\u00a0JF, Brown\u00a0DM et\u00a0al (2016) Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123:2376\u20132385","journal-title":"Ophthalmology"},{"key":"2110_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajo.2018.04.010","volume":"191","author":"N Holekamp","year":"2018","unstructured":"Holekamp\u00a0N, Campbell\u00a0J, Almony\u00a0A et\u00a0al (2018) Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. Am J Ophthalmol 191:83\u201391","journal-title":"Am J Ophthalmol"},{"key":"2110_CR13","unstructured":"https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/. Zugegriffen: 6. Sept. 2023"},{"key":"2110_CR14","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im\u00a0JHB, Jin\u00a0YP, Chow\u00a0R, Yan\u00a0P (2022) Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A\u00a0systematic review and meta-analysis. Surv Ophthalmol 67:1244\u20131251","journal-title":"Surv Ophthalmol"},{"key":"2110_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02637-2","author":"R Khoramnia","year":"2023","unstructured":"Khoramnia\u00a0R, Nguyen\u00a0QD, Kertes\u00a0PJ et\u00a0al (2023) Exploring the role of retinal fluid as a\u00a0biomarker for the management of diabetic macular oedema. Eye. https:\/\/doi.org\/10.1038\/s41433-023-02637-2","journal-title":"Eye"},{"key":"2110_CR16","doi-asserted-by":"publisher","first-page":"18242","DOI":"10.1038\/s41598-022-22838-1","volume":"12","author":"JF Korobelnik","year":"2022","unstructured":"Korobelnik\u00a0JF, Daien\u00a0V, Faure\u00a0C et\u00a0al (2022) Two year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema. Sci Rep 12:18242","journal-title":"Sci Rep"},{"key":"2110_CR17","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik\u00a0JF, Do\u00a0DV, Schmidt-Erfurth\u00a0U et\u00a0al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:2247\u20132254","journal-title":"Ophthalmology"},{"key":"2110_CR18","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1167\/iovs.15-16793","volume":"56","author":"K Kovacs","year":"2015","unstructured":"Kovacs\u00a0K, Marra\u00a0KV, Yu\u00a0G et\u00a0al (2015) Angiogenic and Inflammatory Vitreous Biomarkers Associated With Increasing Levels of Retinal Ischemia. Invest Ophthalmol Vis Sci 56:6523\u20136530","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2110_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10654-019-00560-z","volume":"35","author":"JQ Li","year":"2022","unstructured":"Li\u00a0JQ, Welchowski\u00a0T, Schmid\u00a0M et\u00a0al (2022) Prevalence, incidence and future projection of diabetic eye disease in Europe: a\u00a0systematic review and meta-analysis. Eur J Epidemiol 35:11\u201323","journal-title":"Eur J Epidemiol"},{"key":"2110_CR20","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1177\/1120672119899627","volume":"30","author":"J Schiefelbein","year":"2020","unstructured":"Schiefelbein\u00a0J, M\u00fcller\u00a0M, Kern\u00a0C et\u00a0al (2020) Gender-related differences in patients treated with intravitreal anti-vascular endothelial growth factor medication for diabetic macular oedema. Eur J Ophthalmol 30:1410\u20131417","journal-title":"Eur J Ophthalmol"},{"key":"2110_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41433-021-01624-9","volume":"36","author":"S Sivaprasad","year":"2022","unstructured":"Sivaprasad\u00a0S, Ghanchi\u00a0F, Kelly\u00a0SP et\u00a0al (2022) Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes. Eye 36:64\u201371","journal-title":"Eye"},{"key":"2110_CR22","unstructured":"Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augen\u00e4rzte Deutschlands. Therapie des diabetischen Makula\u00f6dems. Stand 2019"},{"key":"2110_CR23","doi-asserted-by":"publisher","first-page":"100954","DOI":"10.1016\/j.preteyeres.2021.100954","volume":"84","author":"A Uemura","year":"2021","unstructured":"Uemura\u00a0A, Fruttiger\u00a0M, D`Amore\u00a0PA et\u00a0al (2021) VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res 84:100954","journal-title":"Prog Retin Eye Res"},{"key":"2110_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00347-018-0793-y","volume":"116","author":"M Ulbig","year":"2019","unstructured":"Ulbig\u00a0M, H\u00f6h\u00a0H, Schmickler\u00a0S, (POLARIS-Studiengruppe) (2019) Treatment reality with ranibizumab in clinical routine use for patients with diabetic macular edema : 1\u2011year results of the German POLARIS cohort. Ophthalmologe 116:631\u2013639","journal-title":"Ophthalmologe"},{"key":"2110_CR25","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells\u00a0JA, Glassman\u00a0AR, Ayala\u00a0AR et\u00a0al (2016) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a\u00a0comparative effectiveness randomized clinical trial. Ophthalmology 123:1351\u20131359","journal-title":"Ophthalmology"},{"key":"2110_CR26","unstructured":"Wykoff C, (PHOTON Studiengruppe) (2023) EURETINA Congress 2023 Amsterdam, 5.\u20138. https:\/\/euretina.softr.app\/amsterdam-abstract?recordId=recjxiiMs3zg4gTiA"},{"key":"2110_CR27","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.3390\/cells11213362","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang\u00a0J, Zhang\u00a0C, Gu\u00a0L et\u00a0al (2022) Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells 11:3362","journal-title":"Cells"},{"key":"2110_CR28","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s13300-018-0513-2","volume":"9","author":"F Ziemssen","year":"2018","unstructured":"Ziemssen\u00a0F, Wachtlin\u00a0J, Kuehlewein\u00a0L et\u00a0al (2018) Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a\u00a0Non-interventional, Multicenter Study in Germany. Diabetes Ther 9:2271\u20132289","journal-title":"Diabetes Ther"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-02110-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:17:08Z","timestamp":1730305028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-02110-9"}},"subtitle":["24-Monats-Ergebnisse der deutschen Kohorte behandlungsnaiver Patienten mit diabetischem Makula\u00f6dem unter Therapie mit intravitrealem Aflibercept","The 24-month results of the German cohort of treatment-na\u00efve patients with diabetic macular edema receiving intravitreal aflibercept"],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2110"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-02110-9","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M. Ulbig macht folgende Angaben: Grants or contracts from any entity: Alimera, Astrazeneca, Bayer, Novartis, Roche. C.K. Brinkmann macht folgende Angaben: Grants or contracts from any entity: Alimera, Appelis, Afidera, Bayer, Novartis, SandozHexal, Santhera, Teleon. Consulting fees: Abbvie, Bayer. Payment or honoratia for lectures, presentations, speakers bureaus, manuscript writing or educational events: Alimera, Appelis, Afidera, Bayer, Novartis, SandozHexal, Santhera, Thea Pharma, Teleon. Support for attending meetings and\/or travel: Alimera, Appelis, Afidera, Bayer, Novartis, SandozHexal, Santhera, Thea Pharma, Teleon, Ursapharm. A. Mirshahi macht folgende Angaben: Grants or contracts from any entitity: Alimera Sciences, Bayer, Carekom, Eyefox, Glaukos, Johnson & Johnson, Novartis, Optimed, Rodenstock, Santen, Ziemer Ophthalmics. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Bayer. Participation on a Data Safety Monitoring Board or Advisory Board: Bayer. H. Hoerauf macht folgende Angaben: Grants or contracts from any entity: Bayer, Novartis, Roche, Abbvie. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Bayer, Novartis, Roche, Abbvie, Biogen, Thea, Alcon. Participation on a Data Safety Monitoring Board or Advisory Board: Bayer, Alcon, Roche, Stadapharm, Abbvie. Stock or stock options: Bayer, Roche, Novartis. H. Allmeier is a full-time employee of Bayer CC AG. He was the overall responsible for the conduct of the Auriga study. T. Machewitz is a full-time employee of Bayer VitalGmbH and was the responsible study statistician\u00a0and he declares stock or stock options from Bayer. P. Scholz is a full-time employee of Bayer VitalGmbH. G. Keramas is a full-time employee of Bayer VitalGmbH. R. Khoramnia macht folgende Angaben: Grants or contracts from any entity: Bayer, Roche, Chengdu Kanghong, Alimera, Novartis, Opthea. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Bayer, Roche, Abbvie, Alimera, Novartis, Heidelberg Engineering, Apellis. Support for attending meetings and\/or travel: Bayer, Roche, Abbvie, Alimera, Novartis, Heidelberg Engineering, Apellis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Die Daten dieses Beitrages basieren auf einer nicht-interventionellen Beobachtungsstudie an Menschen, bei der klinische Daten aus der klinischen Behandlungsroutine dokumentiert wurden. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}